Wednesday, it was announced by Biogen Idec Inc. that its experimental drug has passed a late-stage trial and has even achieved its main goal, according to a latest report.

The drug has been developed to treat patients with hemophilia B, which was aimed at controlling bleeding in its late stage experiment. And the firm says that a single injection was able to do the same.

It is being said that the long-lasting clotting factor injection helped in control of bleeding in 90.4% of the total number of episodes. The injection is collaboratively being developed with Swedish Orphan Biovitrum.

Biogen has previously also developed drugs named Avonex and Tysabri to treat multiple sclerosis, the report finds. And the study dubbed B-LONG has raised its hopes to see another promising of it drug in the market. The company is seeking to submit an approval application by the first half of 2013 now to the U. S. Food and Drug Administration.

As per the report, common side effects included influenza, joint pain, nasopharyngitis and hypertension or headache. A severe condition though included obstructive uropathy that causes blocking of urine. But, continued treatment cured the same.

"One can never predict the outcome. But we're hopeful that we will see good results", said Biogen's hemophilia program's chief medical officer Glenn Pierce.